Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
XenTech logo — Premium quality preclinical oncology CRO, pioneering the PDX...

XenTech

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.

Founded 2006 France France 36 employees Seed Total: $600.00K Biotechnology, Health Care +1

General Information

Company Name XenTech
Founded Year 2006
Location France France
Employees 36
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with XenTech. To contact XenTech, visit xentech.eu.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does XenTech compare?

A PDF of XenTech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting XenTech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About XenTech

XenTech is a biotech/Contract Research Organization (CRO) founded in 2006 in France. The company specializes in translational research in oncology, offering preclinical services to assess the anti-cancer potential of drug candidates, including PDX and CDX. With a slogan of "Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years," XenTech has positioned itself as a leader in the industry. In addition to its services, XenTech also conducts internal R&D programs aimed at correlating drug response with molecular features of tumors, and identifying cancer biomarkers and therapeutic targets. The company secured a €600.00K Seed Round investment on 31 October 2008, with the investment coming from Aurinvest. With its focus on oncology and the growing demand for personalized medicine, XenTech is well-positioned to capitalize on the increasing emphasis on targeted therapies in the field of cancer treatment. The company's combination of preclinical services, internal R&D, and pioneering PDX technology make it an attractive prospect for investors looking to support advancements in oncology research.

Business keywords: oncology, preclinical research, drug efficacy evaluation, biomarker identification, therapeutic target identification, PDX technology, patient-derived tumor xenografts, contract research organization, in vivo assays, in vitro assays, translational research, biotech, cancer research, R&D programs

Services & Products

Development of preclinical drug testing models
profiling studies
and innovative solutions for drug development in oncology

Target Customers

Biopharmaceutical companies academic institutions research hospitals and cancer research organizations

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €600.00K 1
Aurinvest
Aurinvest
31 Oct 2008
Non Equity Assistance Undisclosed 1
IncubAlliance Paris-Saclay
25 Apr 2006

XenTech Alternatives & Competitors

View All Alternatives
XenTech vs
Champions Oncology, Inc.
Champions Oncology, Inc. United States

US-based, End-to-End Oncology Pharmacology Solutions CRO

IPO
183 employees
Biotechnology, Health Care
Compare XenTech vs Champions Oncology, Inc.
XenTech vs
BioReperia
BioReperia Sweden

Accelerating drug discovery and predicting the best cancer treatment for you!

Series A
19 employees
Biopharma, Biotechnology
XenTech vs
Kurome Therapeutics, Inc.
Kurome Therapeutics, Inc. United States

A preclinical stage company focused on subverting cancer's ability to evade therapy.

Series A
6 employees
Biotechnology, Health Care
Also compare with: XenTech vs INOVOTION INOVOTION View all alternatives

FAQ About XenTech

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.
XenTech was founded in 2006.
XenTech is headquartered in France.
XenTech operates in Biotechnology, Health Care and Life Sciences. Its work centres on oncology, preclinical research, drug efficacy evaluation and biomarker identification. Its customers include Biopharmaceutical companies, academic institutions and research hospitals.
XenTech has approximately 36 employees.
XenTech has completed 2 funding rounds, raising a total of $600.00K. The latest funding stage is Seed.
XenTech offers: Development of preclinical drug testing models, profiling studies, and innovative solutions for drug development in oncology.
Top alternatives and competitors to XenTech include Champions Oncology, Inc., BioReperia, Kurome Therapeutics, Inc., Oncomatryx Biopharma, Cellvax. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XenTech and Champions Oncology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for XenTech, https://bouncewatch.com/company/xentech, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout